The DOI matches its Crossref record; 32 of the 44 references it cites were found in a registry or an index, and 12 are not checked yet; none of the 37 sources its claims cite is checked for support yet.
p53 Deficiency Rescues the Adverse Effects of Telomere Loss and Cooperates with Telomere Dysfunction to Accelerate Carcinogenesis
Open accessAbstract
Maintenance of telomere length and function is critical for the efficient proliferation of eukaryotic cells. Here, we examine the interactions between telomere dysfunction and p53 in cells and organs of telomerase-deficient mice. Coincident with severe telomere shortening and associated genomic instability, p53 is activated, leading to growth arrest and/or apoptosis. Deletion of p53 significantly attenuated the adverse cellular and organismal effects of telomere dysfunction, but only during the earliest stages of genetic crisis. Correspondingly, the loss of telomere function and p53 deficiency cooperated to initiate the transformation process. Together, these studies establish a key role for p53 in the cellular response to telomere dysfunction in both normal and neoplastic cells, question the significance of crisis as a tumor suppressor mechanism, and identify a biologically relevant stage of advanced crisis, termed genetic catastrophe.
Checked 2026-10-06 · 12 references not checked yet
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In telomerase-deficient (mTR−/−) mice, critically short telomeres activate p53, and deleting p53 rescues the resulting apoptosis and cell-cycle arrest — but only during early "crisis." Loss of telomere function and p53 deficiency cooperate to initiate transformation, while telomerase reconstitution mainly benefits later stages of tumorigenesis.
Key findings
- Critical telomere shortening activates p53: p53 protein was detectable in G6 mTR−/− testis but not in mTR+/+ or G6 mTR−/− p53−/− littermates; >80% of G4 and G6 MEFs stained positive for p53 at passage 6 versus 21% of mTR+/+ MEFs. p21CIP1/WAF1 rose 3- to 4-fold in G6 versus G2 mTR−/− p53+/+ MEFs, and p53-dependent CAT reporter activity increased ~2-fold.
- p53 loss rescued telomere-dysfunction phenotypes early but not late: 15% of G4–G6 mTR−/− mice (86/565) were p53−/− versus 26% of G7–G8 mice (24/91) (p = 0.015); all G5 mTR−/− p53−/− testes had normal histology, but 3 of 7 G6 and all five G7–G8 samples showed germ cell depletion. G6 mTR−/− p53−/− MEFs showed a 3-fold increase in chromosome fusions (1.65, SD 2.59 vs 0.42, SD 0.71 per metaphase; p = 0.012), with no change in telomere length (75% reduction regardless of p53 status).
- Telomere dysfunction cooperated with p53 deficiency to initiate transformation: adding mTR suppressed Myc/RAS focus formation in G6 mTR−/− p53−/− MEFs, but mTR-transfected foci had higher subcloning efficiency (23/26, 89%) than vector foci (19/32, 59%; p = 0.018). Tumor formation in SCID mice was similar between groups.
- The authors propose dividing crisis into p53-dependent "early crisis" and p53-independent "genetic catastrophe," questioning crisis as a tumor suppressor mechanism.
Methods
- Mouse genetics: mTR+/− mice crossed with p53+/− mice to generate successive generations (G1–G8) of mTR−/− animals with p53+/+, +/−, and −/− genotypes in a mixed WW6/C57BL/6 background; p53 status maintained heterozygous during matings.
- Cellular/organ assays: immunoblotting and immunohistochemistry for p53 and p21, pG13CAT reporter assays, testis histology with TUNEL, BrdU/propidium iodide FACS cell-cycle profiles, flow FISH telomere length, and metaphase spreads for chromosome fusions.
- Transformation assays: Myc/RAS cotransfection of early-passage MEFs with empty vector or an mTR genomic fragment, scoring focus formation, subcloning efficiency, and tumor formation after subcutaneous injection into SCID mice.
Limitations
- Stated: the mechanisms by which tumorigenic potential is maintained in late stages of tumorigenesis despite telomere dysfunction "remain to be determined"; whether loss of TRF2 binding, short telomeres, or fusion-bridge-breakage cycles mediate the p53 induction described also remains undetermined.
- Evident from the text: the G7–G8 genotype comparison rests on small numbers (24 of 91 mice), and all mice are in a mixed genetic background, which the authors note required cousin mating to avoid substrains.
- Evident from the text: the transformation data are from cultured MEFs and SCID xenografts, and tumor weights/efficiency between mTR and vector lines were not significantly different, so the in vivo relevance of the initiation advantage is inferred rather than directly demonstrated.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
40 Own interpretation · 39 Own result · 21 Not checked yet · 6 Own method · 4 No basis given · 1 Check pending
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Correspondingly, the loss of telomere function and p53 deficiency cooperated to initiate the transformation process.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Coincident with severe telomere shortening and associated genomic instability, p53 is activated, leading to growth arrest and/or apoptosis.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This activity was strictly dependent upon p53, since p53−/− and G6 mTR−/− p53−/− MEF cultures showed only background levels of CAT activity.”
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found that p53 mediates the adverse effects of critically shortened telomeres.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As shown in Figure 3A, DNA content analyses of G6 mTR−/− p53+/+ MEFs revealed a profile consistent with a biphasic block as evidenced by marked accumulation of cells in G1 and G2/M phases.”
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A check of a cited source is scheduled, or we don’t hold its full text yet; the claim is checked once it runs.
In the paper
“Indeed, analysis of metaphase spreads derived from G6 mTR−/− p53+/+ MEFs showed a rate of 0.42 (SD 0.71) chromosomal fusions per metaphase, a rate consistent with previous studies (Figure 3D) (Blasco et al. 1997; Greenberg et al. 1999; Rudolph et al. 1999”
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, p53-independent cell death becomes a more consistent feature in G7 and G8, since all of the five G7–G8 mTR−/− p53−/− testis samples showed significant germ cell depletion microscopically (Figure 2D).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, a relative increase in p53−/− mice was evident in G7 and G8 mTR−/− background (24% and 38%, respectively).”
plaincorrelationaln = 91 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Gross testis size was consistently rescued to near normal in G6 mTR−/− p53−/− mice compared to G6 mTR−/− p53+/+ littermates (see Figure 2A for representative comparison).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, loss of telomere function and p53 deficiency can cooperate to enhance transformation.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 36
- The quote only partly states this claim. 1
- Probably not a substantial claim. 16
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Deletion of p53 significantly attenuated the adverse cellular and organismal effects of telomere dysfunction, but only during the earliest stages of genetic crisis.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast, mTR+/+ p53+/+ MEF cultures demonstrated 35% of cells in S phase and only 13% in G2/M.”
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In mTR+/+ testis, p53 status did not affect testicular volume or significantly alter the cytoarchitecture of seminiferous tubules (Figure 2A and Figure 2B).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Whereas only 21% of the mTR+/+ MEFs at passage 6 stained positive for p53, more than 80% of MEFs derived from G4 and G6 exhibited strong immunoreactivity to p53 (Figure 1B, compare [a] with [b] and [c]).”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In male germ cells and lymphocytes, telomere loss elicits a strong apoptotic response, whereas MEFs experience a potent biphasic cell cycle block.”
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Whereas all G5 mTR−/− p53−/− testes exhibited normal histology, 3 of 7 G6 mTR−/− p53−/− samples still showed varying degrees of pathology (Table 1).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Accordingly, BrdU incorporation assay showed that 36% of the G6 mTR−/− p53+/+ cells were in G1 phase, 3% were in S phase, and 40% were in G2/M (Figure 3A, top panel).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Immunoprecipitation and Western blot analysis readily detected p53 in lysates from G6 mTR−/− testis, but not in lysates derived from age-matched mTR+/+ testis or from G6 mTR−/− p53−/− littermate controls (Figure 1A).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“This induction of p53 coincides with the dramatic increase in apoptosis (as assessed by TUNEL) and decreased cellularity in the G6 mTR−/− testis (Lee et al. 1998”
What the sources say
- Not checked yetcites Lee et al. 1998 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Significantly, loss of p53 rescues the cell cycle arrest in MEFs and the apoptotic elimination of male germ cells.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“loss of p53 abrogated this block.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Significantly, 15% of the G4–G6 mTR−/− mice (86 out of 565 mice) were p53−/− compared to 26% of the G7–G8 mTR−/− mice (24 of 91 mice) (p = 0.015 by Fisher’s two-sided t test) (Figure 1E).”
plaincorrelationaln = 565 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“By comparison, G6 mTR−/− p53−/− MEFs exhibited 1.65 (SD 2.59) fusions per metaphase, a 3-fold increase (p = 0.012).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the case of MEFs, this arrest occurs in concert with the stabilization and activation of the p53 protein, evident in p53-dependent reporter assays and activation of p21CIP1/WAF1.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similar differences were observed in low-density seeding experiments (data not shown).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In human cells, a critical telomere length is eventually reached that induces cellular senescence, thus limiting the replicative capacity of cultured cells at the Hayflick limit (Hayflick and Moorhead 1961”
What the sources say
- Not checked yetcites Hayflick and Moorhead 1961 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
In the paper
“In primary cells deficient for Rb and p53, continued cellular growth beyond the Hayflick limit results in severe telomere shortening, marked genetic instability, and massive cell death—a period referred to as crisis (Counter et al. 1992”
What the sources say
- Not checked yetcites Counter et al. 1992 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Ectopically expressed hTERT maintains telomere length and allows unlimited growth (Bodnar et al. 1998; Counter et al. 1998; Vaziri and Benchimol 1998”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The notion that telomere function may indeed be required for immortalization is supported by the frequent activation of telomerase or ALT in human cancers (Kim et al. 1994; Bryan et al. 1995”
What the sources say
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The telomere signal that activates this senescent program operates through the RB and p53 pathways, since cell division beyond the Hayflick limit can occur after antisense neutralization (Hara et al. 1991”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“Telomerase is comprised of essential catalytic (telomerase reverse transcriptase [TERT]) and RNA components (telomerase RNA [TR]) (reviewed in Greider 1998”
What the sources say
- Not checked yetcites Greider 1998 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Strikingly, as mTR−/− mice advance with age and generation, an increase in cancer incidence is observed presumably due to increased genetic instability caused by telomere shortening, repeated chromosomal fusion-bridge-breakage cycles, and chromosomal loss (Rudolph et al. 1999”
What the sources say
- Not checked yetcites Rudolph et al. 1999 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Due to the very long telomeres of Mus musculus, critical reduction in telomere length and chromosomal instability is only seen following extensive passage of mTR−/− cells (Niida et al. 1998”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The RNA subunit provides the template for telomere repeat synthesis (Greider and Blackburn 1989; Yu et al. 1990”
What the sources say
- Not checked yetcites Greider and Blackburn 1989
- Not checked yetcites Yu et al. 1990
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“although immortalization of some epithelial cells requires not only TERT expression but also compromise of the RB pathway (Kiyono et al. 1998”
What the sources say
- Not checked yetcites Kiyono et al. 1998 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although loss of telomere and p53 function facilitates initiation of transformation, the reconstitution of telomerase activity greatly improved the capacity of transformed foci to yield immortal cultures.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Because G2 mTR−/− and G6 mTR−/− MEFs both lack telomerase activity, we conclude that telomere shortening or associated chromosome fusions and breakage rather than telomerase deficiency per se signals to p53 and accounts for p21CIP1/WAF1 induction.”
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, the rampant genetic instability of the G7 and G8 mTR−/− p53−/− cells is associated with loss of cell viability despite p53 deficiency, implying that advanced genomic catastrophe gives way to a p53-independent process.”
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These results indicate that telomere dyfunction acts synergistically with p53 deficiency to initiate malignant transformation, presumably by enhancing genetic instability.”
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Continued proliferation in the absence of the p53 checkpoint may lead to an increased loss of telomere sequences and therefore account for the increased frequency of chromosome fusions.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For these matings, the p53 status was maintained in the heterozygous state to avoid potential broad genomic effects arising from p53 deficiency.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The ability of exogenous telomerase to reduce focus formation in p53 null cells with short dysfunctional telomeres suggests that genetic instability associated with telomere loss can serve as an engine driving initiation of transformation, but only in the absence of functional p53 (Figure 5).”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Focus formation reflects the earliest stages of oncogenic transformation.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Early crisis accounts for efficient germ cell depletion in G6 mTR−/− p53+/+, whereas the altered histology of G7 and G8 mTR−/− p53−/− testis provides experimental support for late crisis.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Together, these data indicate that p53 deficiency restores neither telomere length nor function in the telomerase-deficient mouse.”
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“This mating scheme also produced p53+/+ and p53−/− littermate controls for each mTR−/− generation.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“Telomere shortening in mTR−/− mice results in loss of telomere function and chromosome end-to-end fusion (Blasco et al. 1997; Rudolph et al. 1999”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The observation that mTR expression facilitates subcloning efficiency of Myc/RAS-transformed late-generation mTR−/− cells supports the importance of telomere maintenance mechanisms during later stages of carcinogenesis.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Induction of double strand breaks in DNA by ionizing radiation or genotoxic chemotherapy leads to the rapid stabilization of p53 through phosphorylation of its N terminus (Shieh et al. 1997; Siliciano et al. 1997”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Together with previous work, our data indicated that, first, during the early stages of tumorigenesis, cells suffer telomere shortening, and second, that telomerase activation is advantageous primarily in later stages of tumorigenesis.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Many human tumors that are telomerase positive still have short telomeres.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cells with short telomeres and intact p53-mediated DNA damage responses may be more efficiently “culled” from the population (via apoptosis or arrest); therefore, p53 null cells may accumulate more end-to-end fusions than their p53+/+ counterparts.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Once both telomere function and p53 have been impaired, the fate of the cell is unpredictable and depends on other stochastic genetic changes.”
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“This stabilization results in either cell cycle arrest via transcriptional induction of the p21CIP1/WAF1 CDK inhibitor or apoptosis (reviewed in Levine 1997”
What the sources say
- Not checked yetcites Levine 1997 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Loss of p53 can circumvent this checkpoint, leading eventually to p53-independent apoptosis, perhaps as a consequence of uncontrolled chromosome fusion-bridge-breakage cycles and progressive genomic instability.”
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, both the apoptotic response and cell cycle arrest induced by telomere dysfunction are mediated by p53.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For telomere length determination of MEFs, littermate MEF cultures were assayed simultaneously to reduce experimental variability.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“At least two independent determinations of the same cultures were performed.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Day to day variations in the linearity of the flow cytometer were controlled by the use of FITC-labeled fluorescence beads (Flow Cytometry Standards Corporation).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Three independent age-matched sets of animals were used.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In mTR−/− INK4a−/− mice, it is likely that telomere dysfunction activates p53 via a DNA damage signaling pathway and results in growth arrest or apoptosis, limiting the efficiency of carcinogenesis”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
The signals and pathways mediating the cellular responses associated with telomere dysfunction have yet to be defined in mammalian cells.
“The signals and pathways mediating these cellular responses associated with telomere dysfunction have yet to be defined in mammalian cells.”
The paper relies on this without support.
The RAD9 and MEC1 DNA damage response pathways in yeast are similar to the p53 checkpoint in mammalian cells.
“The RAD9 and MEC1 DNA damage response pathways in yeast are thought to be similar to the p53 checkpoint in mammalian cells.”
The paper relies on this without support.
The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
“The mTR−/− mouse serves as a model to study the consequences of telomere loss in vivo.”
The paper relies on this without support.
Focus formation reflects the earliest stages of oncogenic transformation.
“Focus formation is thought to reflect the earliest stages of oncogenic transformation.”
The paper relies on this without support.
Human cells require inactivation of Rb and/or p53 to bypass the major checkpoint that limits replicative lifespan: cellular senescence.
“Human cells require inactivation of Rb and/or p53 to bypass the major checkpoint that limits replicative lifespan: cellular senescence.”
The paper relies on this without support.
Rb/p53 inactivation allows continued cell division beyond senescence, progressive telomere shortening, and entry into crisis, from which only rare survivors emerge.
“Rb/p53 inactivation allows continued cell division beyond senescence, progressive telomere shortening, and entry into crisis, from which only rare survivors will emerge.”
The paper relies on this without support.
Many human tumors that are telomerase positive still have short telomeres.
“The fact that many human tumors that are telomerase positive still have short telomeres supports the idea that telomerase activation occurs late in tumorigenesis.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although enabling cellular growth and survival and masking degenerative phenotypes, these mTerc -/ -p53 mutant mice experience a dramatic increase in cancer incidence, shift in tumor spectrum toward epithelial cancers, and accumulation of marked chromosomal aberrations targeting cancerrelevant loci for amplification and deletion (4-6).”
From Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse (2007) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Specifically, p53 deficiency results in nearcomplete rescue of adverse cellular consequences associated with telomere dysfunction, including cellular growth arrest and apoptosis, progressive organ system atrophy, and physiological compromise.”
From Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse (2007) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Telomere dysfunction appears to engage the p53-dependent double-stranded break DNA damage pathway.”
From Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse (2007) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When the p53 checkpoint is compromised, unchecked genomic instability caused by telomere dysfunction accelerates tumorigenesis as seen in late-generation mTerc -/ -p53 mutant mice (4, 5).”
From Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse (2007) · cites this paper as [4]
Experimental — accuracy not yet measuredIn the citing paper
“By contrast, p53 inactivation alone is sufficient to avoid telomere-induced senescence and apoptosis in mice49,50.”
From Telomeres in cancer: tumour suppression and genome instability (2017) · cites this paper as [49]
In the citing paper
“In the absence of telomerase, continued cell division results in telomere shortening, loss of ‘capping’ function, and p53 activation12-15.”
From Telomere dysfunction induces metabolic and mitochondrial compromise (2011) · cites this paper as [15]
In the citing paper
“p53 deficiency markedly attenuates the degenerative phenotypes associated with telomere dysfunction, whereas constitutively activated p53 accelerates ageing phenotypes15-18.”
From Telomere dysfunction induces metabolic and mitochondrial compromise (2011) · cites this paper as [15]
In the citing paper
“Critically short telomeres induce cellular and tissue defects through checkpoint signaling pathways that converge on the p53 tumor suppressor protein, a well-known cellular stress sensor that enforces cell cycle arrest or cell death in response to diverse stimuli including activated oncogenes, DNA damage and hypoxia (69)”
From Telomeres and telomerase in cancer (2010) · cites this paper as [69]
In the citing paper
“The downstream effector pathways of telomere-induced senescence are largely p53-dependent96, but there may be involvement of the retinoblastoma protein (RB) pathway in some settings97.”
From The telomere syndromes (2012) · cites this paper as [96]
In the citing paper
“Importantly, removal of p53 function rescued many of the cellular defects despite the presence of critically short telomeres, including growth arrest in cell culture, testicular atrophy, intestinal and germ cell apoptosis46.”
From Telomere dysfunction and tumour suppression: the senescence connection (2008) · cites this paper as [46]
In the citing paper
“recent reports of the effect of the mTR deletion in different genetic backgrounds (17, 18) suggest that the role of telomerase in cancer development could be highly context dependent (19).”
From Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death (1999) · cites this paper as [18]
Citations
Cites
The serial cultivation of human diploid cell strains
Hayflick, L., & Moorhead, P. S. (1961) · Experimental Cell Research · doi:10.1016/0014-4827(61)90192-6 · Cited by 8,508
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“INK4a2/2 centration of 10 mM for 3.5 hr. Cells were processed as previouslymice lack functional p19ARF, a modulator of p53 function described (Serrano et al., 1997).activated by inappropiate oncogene activation, but re- tain intact DNA damage–induced p53 activation (Kamijo MEF Transformation…”
MethodInfluentialExtension of Life-Span by Introduction of Telomerase into Normal Human Cells
Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C.-P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., & Wright, W. E. (1998) · Science · doi:10.1126/science.279.5349.349 · Cited by 4,975
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,911
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA
Blasco, M. A., Lee, H.-W., Hande, M. P., Samper, E., Lansdorp, P. M., DePinho, R. A., & Greider, C. W. (1997) · Cell · doi:10.1016/s0092-8674(01)80006-4 · Cited by 2,108
Self-citation
Cited by
Sorted by citations
Items 401–500 of 975
Raval-Fernandes, S., Kickhoefer, V. A., Ramirez, C. M., & Rome, L. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0770 · Cited by 56
“Loss of p53 enhances the initiation of malignant transformation in Terc / mouse embryonic fibroblasts (58).”
Perera, S. A., Maser, R. S., Xia, H., McNamara, K. L., Protopopov, A. I., Chen, L., Hezel, A. F., Kim, C. F., Bronson, R. T., Castrillón, D. H., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn050 · Cited by 59
“This is consistent with the hypothesis that cells with shortened telomeres experience crisis and undergo apoptosis when the p53 checkpoint is intact, but progress towards malignancy in the absence of p53 [5,6,30,33,34].”
InfluentialSelf-citationUsing Mice to Examine p53 Functions in Cancer, Aging, and LongevityPreprint
Donehower, L. A. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001081 · Cited by 59
“Crossing of these mice into a p53 null background resulted in a loss of the aging phenotypes associated with telomerase deficiency (Chin et al. 1999).”
Telomere function and regulation from mouse models to human ageing and disease
Jones-Weinert, C. W., Mainz, L., & Karlseder, J. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00800-5 · Cited by 63
“Therefore, if checkpoints are lost, telomere shortening is tumorigenic 25 .”
Beccaria, M. G., Martínez, P., Méndez‐Pertuz, M., Martínez, S., Blanco‐Aparicio, C., Cañamero, M., Mulero, F., Ambrogio, C., Flores, J. M., Megías, D., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404497 · Cited by 57
“Moreover, these anti-tumorigenic effects of short telomeres owing to telomerase deficiency are abrogated in the absence of p53 (Chin et al , 1999; Greenberg et al , 1999).”
Tümpel, S., & Rudolph, K. L. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06547.x · Cited by 59
Trková, M., Procházková, K., Krutilkova, V., Sumerauer, D., & Sedláček, Z. (2007) · Cancer · doi:10.1002/cncr.22834 · Cited by 55
Telomere dysfunction instigates inflammation in inflammatory bowel disease
Chakravarti, D., Lee, R., Multani, A. S., Santoni, A., Keith, Z., Hsu, W., Chang, K., Reyes-Uribe, L., Rashid, A., Wu, C., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2024853118 · Cited by 54
“However, given the association of telomerase reactivation to the initiation of cancers especially in the context of loss of p53/p21 (34, 36) or RB/p16 senescence checkpoints (65), caution should be taken in the ideation and design of such therapeutic approaches.”
BackgroundSelf-citationAging, Graying and Loss of Melanocyte Stem Cells
Sarin, K. Y., & Artandi, S. E. (2007) · Stem Cell Reviews and Reports · doi:10.1007/s12015-007-0028-0 · Cited by 54
“Telomere shortening can induce cellular senescence or programmed cell death, as the protective cap that constitutes the telomere is lost leading to a DNA damage response at the telomere end [15, 43] and activation of the tumor suppressor protein p53 [11, 20].”
Self-citationSomatic stem cells and the origin of cancer
Martinez-Climent, J. A., Andreu, E. J., & Prósper, F. (2006) · Clinical & Translational Oncology · doi:10.1007/s12094-006-0035-7 · Cited by 57
Telomere dysfunction: multiple paths to the same end
Harrington, L. A., & Robinson, M. O. (2002) · Oncogene · doi:10.1038/sj.onc.1205084 · Cited by 54
“Although not characterized in detail, the eventual loss of cell viability in mTerc (7/7) p53 (7/7) mice was considered to result from genetic catastrophe ± the accumulation of su cient genetic damage to render a cell unable to perform basic functions required for viability (Chin et al., 1999).”
BackgroundInfluentialNersisyan, L., Hopp, L., Loeffler‐Wirth, H., Galle, J., Loeffler, M., Arakelyan, A., & Binder, H. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01172 · Cited by 55
“On the other hand, only a part of cells acquires immortality at telomere crisis and proceeds to cancerogenesis while the other part becomes apoptotic (71).”
BackgroundGenome instability of ageing stem cells—Induction and defence mechanisms
Burkhalter, M. D., Rudolph, K. L., & Sperka, T. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.01.004 · Cited by 54
Sheng, R., Gu, Z., Xie, M., Wen-xuan, Z., & Ci-yi, G. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.05.054 · Cited by 53
“increasewith age in cardiomyocytes (Chin et al., 1999; Leri et al., 2003; Sano et al., 2007).”
Cell-cycle dysregulation and the molecular mechanisms of prostate cancer
Derek, F. A. (2000) · Frontiers in bioscience · doi:10.2741/amanatullah · Cited by 53
Coutelier, H., Xu, Z., Morisse, M. C., Lhuillier‐Akakpo, M., Pelet, S. B., Charvin, G., Dubrana, K., & Teixeira, M. T. (2018) · Genes & Development · doi:10.1101/gad.318485.118 · Cited by 61
“…that telomerase deficiency/inactivation is linked to increased genome instability, a hallmark of cancer (Blasco et al. 1997; Lee et al. 1998a; Chin et al. 1999; Hanahan and Weinberg 2000; Hackett et al. 2001; Hackett and Greider 2003; Maciejowski et al. 2015; Aunan et al. 2017; Maciejowski…”
Khoo, C. M., Carrasco, D. R., Bosenberg, M. W., Paik, J.-H., & DePinho, R. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700093104 · Cited by 52
Self-citationRadpour, R., Barekati, Z., Haghighi, M. M., Kohler, C., Asadollahi, R., Torbati, P. M., Holzgreve, W., & Zhong, X. Y. (2010) · Modern Pathology · doi:10.1038/modpathol.2009.195 · Cited by 52
Impaired telomere integrity and rRNA biogenesis in PARN‐deficient patients and knock‐out models
Benyelles, M., Episkopou, H., O’Donohue, M.-F., Kermasson, L., Frange, P., Poulain, F., Belen, F. B., Polat, M., Bôle‐Feysot, C., Vives, F. L., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201810201 · Cited by 55
“Since p53 deficiency was previously reported to rescue the deleterious effects of aberrant short telomeres (Chin et al, 1999), we next tested whether the A B C Figure 5.”
Sato, R., Maesawa, C., Fujisawa, K., Wada, K., Oikawa, K., Takikawa, Y., Suzuki, K., Oikawa, H., Ishikawa, K., & Masuda, T. (2004) · Gut · doi:10.1136/gut.2003.027516 · Cited by 52
“25 More continuous telomere shortening beyond the Hayflic limit leads to loss of telomere capping activity, culminating in severe chromosomal instability and massive cell death, referred to as ‘‘crisis/mortality stage 2 (M2)’’.”
Kwon, B. S., Jung, H. S., Song, M.-S., Cho, K. S., Kim, S.-C., Kimm, K., Jeong, J. S., Kim, I.-H., & Lee, S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.06.096 · Cited by 51
Self-citationGenomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer
Danforth, D. N. (2016) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s39384 · Cited by 53
HuR regulates telomerase activity through TERC methylation
Tang, H., Wang, H., Cheng, X., Fan, X., Yang, F., Zhang, M., Chen, Y., Tian, Y., Liu, C., Shao, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04617-7 · Cited by 51
Telomere length variation in biliary tract metaplasia, dysplasia, and carcinoma
Hansel, D. E., Meeker, A. K., Hicks, J. L., Marzo, A. M. D., Lillemoe, K. D., Schulick, R. D., Hruban, R. H., Maitra, A., & Argani, P. (2006) · Modern Pathology · doi:10.1038/modpathol.3800591 · Cited by 57
Telomere length maintenance in aging and carcinogenesis.
Aragona, M., Maisano, R., Panetta, S., Giudice, A., Morelli, M., Torre, I. L., & Torre, F. L. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.5.981 · Cited by 51
Nalapareddy, K., Jiang, H., Gutierrez, L. M. G., & Rudolph, K. L. (2008) · Experimental Gerontology · doi:10.1016/j.exger.2008.09.002 · Cited by 50
“Uncapped, dysfunctional telomeres trigger DNA damage responses that lead to an activation of the p53 pathway (Chin et al., 1999).”
BackgroundGut-specific telomerase expression counteracts systemic aging in telomerase-deficient zebrafish
Maï, M. E., Bird, M., Allouche, A., Targen, S., Şerifoğlu, N., Lopes-Bastos, B., Guigonis, J., Kang, D., Pourcher, T., Yue, J., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00401-5 · Cited by 59
Helicobacter pylori and gastric cancer
BMJ Publishing Group Ltd (1998) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.1998.36857 · Cited by 50
Harada, K., Kurisu, K., Tahara, H., Tahara, E., Ide, T., & 田原, 榮. (2000) · Journal of neurosurgery · doi:10.3171/jns.2000.93.4.0618 · Cited by 50
Siegl‐Cachedenier, I., Muñoz, P., Flores, J. M., Klatt, P., & Blasco, M. A. (2007) · Genes & Development · doi:10.1101/gad.430107 · Cited by 51
“It is important to point out that, in marked contrast to p21 and PMS2 deficiencies, p53 deficiency does not rescue survival of telomerase-deficient mice in spite of the fact p53 deficiency rescues both proliferative defects and apoptosis associated with telomere dysfunction (Chin et al. 1999).”
The Role of Telomerase Expression and Telomere Length Maintenance in Human and Mouse
Nan-PIng, W., & Hodes, R. J. (2000) · Journal of Clinical Immunology · doi:10.1023/a:1017223602293 · Cited by 49
“It was found that mTER deficiency synergized with p53 deficiency to predispose to malignant transformation (62).”
Berardinelli, F., Siteni, S., Tanzarella, C., Stevens, M. F. G., Sgura, A., & Antoccia, A. (2014) · DNA repair · doi:10.1016/j.dnarep.2014.10.009 · Cited by 52
Bartocci, C., Diedrich, J. K., Ouzounov, I., Li, J., Piunti, A., Pasini, D., Yates, J. R., & Denchi, E. L. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.002 · Cited by 52
“For example, the induction of telomere dysfunction in mice results in epithelial cancers with a complex karyotype, indicative of rampant genomic instability (Artandi et al., 2000; Chin et al., 1999).”
BackgroundKomata, T., Kondo, Y., Koga, S., Ko, S.-C., Chung, L. W. K., & Kondo, S. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301327 · Cited by 49
Personalized Risk Assessment in Never, Light, and Heavy Smokers in a prospective cohort in Taiwan
Wu, X., Wen, C. P., Ye, Y., Tsai, M., Wen, C., Roth, J. A., Pu, X., Chow, W., Huff, C. D., Cunningham, S. A., et al. (2016) · Scientific Reports · doi:10.1038/srep36482 · Cited by 48
Age-Related Changes of Claudin Expression in Mouse Liver, Kidney, and Pancreas
D’Souza, T., Sherman‐Baust, C. A., Poosala, S., Mullin, J. M., & Morin, P. J. (2009) · The Journals of Gerontology Series A · doi:10.1093/gerona/glp118 · Cited by 48
Molecular targeting of cancer: Telomeres as targets
Hodes, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151267698 · Cited by 47
Telomeres, oxidative stress, and timing for spontaneous term and preterm labor
Phillippe, M. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2022.04.024 · Cited by 47
Telomere Length Influences Cancer Cell Differentiation In Vivo
Hirashima, K., Migita, T., Sato, S., Muramatsu, Y., Ishikawa, Y., & Seimiya, H. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00136-13 · Cited by 50
“While telomere shortening suppresses cancer formation (9– 12), it sometimes promotes genomic instability and enhances carcinogenesis and the development of malignancy (13).”
The inherited genetics of pancreatic cancer and prospects for secondary screening
Vitone, L. J., Greenhalf, W., McFaul, C., Ghaneh, P., & Neoptolemos, J. P. (2006) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2005.10.007 · Cited by 46
Telomere Dysfunction, Chromosomal Instability and Cancer
Meena, J. K., Rudolph, K. L., & Güneş, Ç. (2015) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-20291-4_3 · Cited by 51
p53 and the regulation of hepatocyte apoptosis: implications for disease pathogenesis
Amaral, J. D., Castro, R. E., Steer, C. J., & Rodrigues, C. M. P. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.09.005 · Cited by 46
Soohoo, C., Shi, R., Lee, T. H., Huang, P., Lu, K. P., & Zhou, X. Z. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.180174 · Cited by 47
Missios, P., Zhou, Y., Guachalla, L. M., von Figura, G., Wegner, A., Chakkarappan, S. R., Binz, T. M., Gompf, A., Hartleben, G., Burkhalter, M. D., et al. (2014) · Nature Communications · doi:10.1038/ncomms5924 · Cited by 49
Westin, E. R., Aykin‐Burns, N., Buckingham, E. M., Spitz, D. R., Goldman, F. D., & Klingelhutz, A. J. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3444 · Cited by 45
“This is in contrast to double knockouts of p53 and telomerase in which frequency of malignancy is dramatically increased (10).”
Song, L. L., Ponomareva, L. V., Shen, H., Duan, X., Alimirah, F., & Choubey, D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008569 · Cited by 45
Altered senescence, apoptosis, and DNA damage response in a mutant p53 model of accelerated aging
Hinkal, G. W., Gatza, C. E., Parikh, N., & Donehower, L. A. (2009) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2009.01.001 · Cited by 45
“Crossing these models to p53 heterozygous or null mice can partially rescue some of the aging phenotypes (Cao et al., 2003; Chin et al., 1999; Lim et al., 2000; Varela et al., 2005).”
Targeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma
Fan, H., Chen, C., Chi, C.-S., Tsai, J., Chiang, K.-L., Chang, Y., Lin, S., & Harn, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010200 · Cited by 48
Rajaraman, S., Choi, J., Cheung, P., Beaudry, V., Moore, H., & Artandi, S. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706485104 · Cited by 44
Self-citationCellular Senescence as a Target in Cancer Control
Vergel, M., Marín, J., Estévez, P., & Carnero, A. (2010) · Journal of Aging Research · doi:10.4061/2011/725365 · Cited by 45
“The kinetics of replicative senescence do not show an abrupt arrest of the whole population, but a gradual decline in the proportion of dividing cells [7], the exact timing of which varies between both cell types and sister clones [8].”
BackgroundLi, D., de Glas, N. A., & Hurria, A. (2015) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2015.08.003 · Cited by 44
“and is likely dependent on both the specific cell types involved and the overall genomic context.(40,41)”
Lechel, A., Manns, M. P., & Rudolph, K. L. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.06.010 · Cited by 44
“p21) play a key role in response to telomere dysfunction [26–29].”
Cox, L. S., & Faragher, R. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7123-x · Cited by 44
Identification of telomere-dependent "senescence-like" arrest in mouse embryonic fibroblasts.
Espejel, S., & Blasco, M. (2002) · Experimental Cell Research · doi:10.1006/excr.2002.5533 · Cited by 47
Pieters, N., Janssen, B. G., Valeri, L., Cox, B., Cuypers, A., Dewitte, H., Plusquin, M., Smeets, K., & Nawrot, T. S. (2015) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2015.02.003 · Cited by 43
Serotonin Transporter and Serotonin Receptors
Adnot, S., Houssaini, A., Abid, S., Marcos, É., & Amsellem, V. (2013) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-38664-0_15 · Cited by 43
Is p53 Involved in Tissue‐Specific Insulin Resistance Formation?
Strycharz, J., Drzewoski, J., Szemraj, J., & Śliwińska, A. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/9270549 · Cited by 45
“Damage and shortening of telomeres form general telomere dysfunctionality, which provokes p53 activation and results in either senescence or apoptosis [89, 90].”
Telomere dynamics in childhood leukemia and solid tumors: a follow-up study
Franco, S., Ozkaynak, M. F., Sandoval, C., Tugal, O., Jayabose, S., Engelhardt, M. M., & Moore, M. A. S. (2003) · Leukemia · doi:10.1038/sj.leu.2402815 · Cited by 43
Lee, J. H., Hong, J., Zhang, Z., Avalos, B. D. L. P., Proietti, C. J., Deamicis, A. R., Pablo Guzmán, G., Lam, H., Garcia, J. M., Roudier, M. P., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg7073 · Cited by 43
Telomere length and telomerase subunits as diagnostic and prognostic biomarkers in Barrett carcinoma
Gertler, R., Doll, D., Maak, M., Feith, M., & Rosenberg, R. (2008) · Cancer · doi:10.1002/cncr.23419 · Cited by 41
The Emerging Role of Telomerase in Cardiac Muscle Cell Growth and Survival
Oh, H., & Schneider, M. D. (2002) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.2002.2018 · Cited by 40
Trade-off between cancer and aging: What role do other diseases play?
Yashin, A. I., Ukraintseva, S. V., Akushevich, I. V., Arbeev, K. G., Kulminski, A. M., & Akushevich, L. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2008.03.006 · Cited by 41
“Introducing the null p53 allele has protected Ku80−/− and mTR−/− mice from premature aging (Vogel et al., 1999; Chin et al., 1999), indicating that the senescence phenotypes were p53-dependent (Lim et al., 2000).”
Delhommeau, F., Thierry, A., Feneux, D., Lauret, E., Leclercq, E., Courtier, M. H., Sainteny, F., Vainchenker, W., & Griscelli, A. B. (2002) · Oncogene · doi:10.1038/sj.onc.1206054 · Cited by 42
“Moreover, lessons learned from knock-out mice have to be considered since carcinogenesis is accelerated when both murine telomerase RNA and p53 genes are inactivated (Chin et al., 1999).”
BackgroundAnisimov, V. N. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00262-7 · Cited by 41
Glioblastoma induces vascular endothelial cells to express telomerase in vitro.
Falchetti, M. L., Pierconti, F., Casalbore, P., Maggiano, N., Levi, A., Larocca, L. M., & D, R. P. M. (2003) · PubMed · Cited by 41
Didier, N., Hourdé, C., Amthor, H., Marazzi, G., & Sassoon, D. A. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201101075 · Cited by 43
“…et al, 2007; Sacco et al, 2010; Vijg, 2000). p53 activation results from DNA damage and telomere shortening leading to cell cycle arrest, death or senescence (Chin et al, 1999; Itahana et al, 2001; Vousden, 2000). p53 also regulates aging and longevity (Pinkston et al, 2006; Vaziri et al, 2001).”
Muñoz-Lorente, M. A., Martínez, P., Tejera, Á., Whittemore, K., Moisés-Silva, A. C., Bosch, F., & Blasco, M. A. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007562 · Cited by 40
MSH2 deficiency abolishes the anticancer and pro‐aging activity of short telomeres
Martínez, P., Siegl‐Cachedenier, I., Flores, J. M., & Blasco, M. A. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2008.00441.x · Cited by 39
“This situation is similar to that previously described for Terc/p53 mice (Chin et al., 1999).”
Telomere shortening and cell fates in mouse models of neoplasia
Artandi, S. E. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02222-5 · Cited by 40
Self-citationTelomere dysfunction and stem cell ageing
Ju, Z., & Rudolph, K. L. (2007) · Biochimie · doi:10.1016/j.biochi.2007.09.006 · Cited by 42
Telomerase is regulated by c-Jun NH2-terminal kinase in ovarian surface epithelial cells.
Matte, M. Y. A.-D., Yang, H., Evans, M. S., Cheng, J. Q., & Kruk, P. A. (2002) · PubMed · Cited by 40
Replication Proteins Influence the Maintenance of Telomere Length and Telomerase Protein Stability
Dahlén, M., Sunnerhagen, P., & Wang, T. S. ‐. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.9.3031-3042.2003 · Cited by 38
Telomerase inhibition and the future management of head-and-neck cancer
McCaul, J. A., Gordon, K., Clark, L., & Parkinson, E. K. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00729-5 · Cited by 39
Telomeres as hotspots for innate immunity and inflammation
Nassour, J., Przetocka, S., & Karlseder, J. (2023) · DNA repair · doi:10.1016/j.dnarep.2023.103591 · Cited by 40
Telomeres and Telomerase in Stem Cells during Aging and Disease
Ju, Z., & Rudolph, K. L. (2006) · KARGER eBooks · doi:10.1159/000092502 · Cited by 39
Biroccio, A., Amodei, S., Antonelli, A., Benassi, B., & Zupi, G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304597200 · Cited by 38
Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A
Gupta, R., Dong, Y., Solomon, P. D., Wettersten, H. I., Cheng, C. J., Min, J., Henson, J. D., Dogra, S. K., Hwang, S. H., Hammock, B. D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411370111 · Cited by 36
“Furthermore, p53 loss cooperates with telomerase dysfunction to promote tumorigenesis (4).”
DNA repair and the immune system: From V(D)J recombination to aging lymphocytes
Rivera-Muñoz, P., Malivert, L., Derdouch, S., Azerrad, C., Abramowski, V., Revy, P., & de Villartay, J. (2007) · European Journal of Immunology · doi:10.1002/eji.200737396 · Cited by 41
The Pleiotropy of Telomerase against Cell Death
Sung, Y. H., Choi, Y. S., Cheong, C., & Lee, H. (2005) · Molecules and Cells · doi:10.1016/s1016-8478(23)13173-6 · Cited by 37
“Since these progressively adverse effects depend on the critical shortening of telomeres eliciting fusion or loss of chromosomes, there is no doubt that the lengthening of telomeres by telomerase has the essential roles in the maintenance of genomic integrity and in the long-term viability of high-renewal organ system…”
Aging and the programmed death phenomena
Skulachev, V. P. (2003) · Topics in current genetics · doi:10.1007/978-3-540-37005-5_8 · Cited by 36
Mouse bites dogma: how mouse models are changing our views of how P53 is regulated in vivo
Wahl, G. M. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401911 · Cited by 37
Telomere Length and Telomerase Activity Impact the UV Sensitivity Syndrome Xeroderma Pigmentosum C
Stout, G. J., & Blasco, M. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3125 · Cited by 35
“Carcinogenesis studies conducted with telomerase-deficient mice in p53-deficient backgrounds have shown that p53 plays a pivotal role in response to telomere dysfunction (45).”
BackgroundMetabolic regulation of oxygen and redox homeostasis by p53: Lessons from evolutionary biology?
Zhuang, J., Ma, W., Lago, C. U., & Hwang, P. M. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.07.026 · Cited by 37
“Telomere shortening can promote premature aging by activating p53 [79].”
D, R. P. M., Sorrentino, A., Pierconti, F., Maggiano, N., Faggi, R., Montano, N., Maira, G., Larocca, L. M., Levi, A., & Falchetti, M. L. (2005) · International Journal of Cancer · doi:10.1002/ijc.21613 · Cited by 35
Mitochondria, its DNA and telomeres in ageing and human population
Zole, E., & Ranka, R. (2018) · Biogerontology · doi:10.1007/s10522-018-9748-6 · Cited by 36
“…and beta (PGC-1a/b, which regulate a vast number of mitochondrial functions, including mitochondrial replication/transcription, OXPHOS, oxidative stress and gluconeogenesis (e.g., Wu et al. 1999) action via the p53 transcription factor (Chin et al. 1999; Sahin and Depinho 2010; Sahin et al. 2011).”
Cellular senescence and neurodegeneration
Holloway, K., Neherin, K., Dam, K. U., & Zhang, H. (2023) · Human Genetics · doi:10.1007/s00439-023-02565-x · Cited by 40
Lopez (2002) · doi:10.1002/cncr.10911 · Cited by 36
“Mice lacking telomerase activity and INK4A tumor suppressor were resistant to malignancy,(26) whereas telomerase-deficient and p53 mutant mice were reported to be more susceptible to malignant transformation.(27) The authors attributed the differential responses to the distinct role of the proteins INK4A and p53 in ev…”
Telomeres in cancer and aging: lessons from the mouse
Blasco, M. A. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00705-x · Cited by 36
Hasty, P. (2004) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2004.09.036 · Cited by 35
The genetics of pancreatic adenocarcinoma: a roadmap for a mouse model
Bardeesy, N. M., Sharpless, N. E., DePinho, R. A., & Merlino, G. T. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0371 · Cited by 35
Self-citationTelomerase and hallmarks of cancer: An intricate interplay governing cancer cell evolution
Kumar, N., & Sethi, G. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216459 · Cited by 35
Trade-Offs Between Cancer and Other Diseases: Do They Exist and Influence Longevity?
Ukraintseva, S. V., Arbeev, K. G., Akushevich, I. V., Kulminski, A. M., Arbeeva, L. S., Culminskaya, I. V., Akushevich, L., & Yashin, A. I. (2010) · Rejuvenation Research · doi:10.1089/rej.2009.0941 · Cited by 35
“5 Introducing the null p53 allele has protected Ku80 (cid:1) = (cid:1) and mTR (cid:1) = (cid:1) mice from premature aging, 6,7 indicating that the senescence phenotypes were p53 dependent.”
Wang, Y., Wang, X., Flores, E. R., Yu, J., & Chang, S. S. (2016) · Aging Cell · doi:10.1111/acel.12476 · Cited by 37
Ito, M., Yurube, T., Kanda, Y., Kakiuchi, Y., Takeoka, Y., Takada, T., Kuroda, R., & Kakutani, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083965 · Cited by 36
“In Western blotting, IL-1βmediated inflammation modestly promoted poly (ADP-ribose) polymerase (PARP) [37] and caspase-9 [38] cleavage, increased B-cell lymphoma 2 (BCL2)-associated X protein (BAX) [39] expression, and decreased BCL2 [39] expression, indicating apoptosis induction through the mitochondrial pathway, an…”
Telomere length maintenance in stem cell populations
Allen, N. D., & Baird, D. M. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.02.004 · Cited by 35
“proliferative defects, but this was accompanied by an increase in the rate of tumour formation [23].”
BackgroundMacnamara, B., Wang, W., Chen, Z., Hou, M., Mazur, J., Gruber, A., & Porwit‐MacDonald, A. (2001) · PubMed · Cited by 35
Disruptive chemicals, senescence and immortality
Carnero, A., Blanco‐Aparicio, C., Kondoh, H., LLeonart, M. E., Martínez-Leal, J. F., Mondello, C., Scovassi, A. I., Bisson, W. H., Amedei, A., Roy, R., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv029 · Cited by 36
Stem Cells: The Pursuit of Genomic Stability
Wyles, S. P., Brandt, E. B., & Nelson, T. J. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151120948 · Cited by 36
“It plays a crucial role in preventing the propagation of DNA-damaged cells [14].”
BackgroundFriend or foe? Telomerase as a pharmacological target in cancer and cardiovascular disease
Ait‐Aissa, K., Ebben, J. D., Kadlec, A. O., & Beyer, A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.003 · Cited by 34
“In the absence of p53, cells with critically short telomeres are able to survive and undergo chromosomal rearrangements that can cooperate with expression of oncogenes to increase transformation efficiency, at least in the short term (25).”
BackgroundPathways for salvage and protection of the heart under stress: novel routes for cardiac rejuvenation
Cannata, A. N., Camparini, L., Sinagra, G., Giacca, M., & Loffredo, F. S. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw106 · Cited by 34
Metadata
- Authors
- Chin, L., Artandi, S. E., Shen, Q., Tam, A., Lee, S.-L., Gottlieb, G. J., Greider, C. W., & DePinho, R. A.
- Affiliations
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Quest Diagnostics (United States) (US)
- Johns Hopkins University (US)
- Corresponding author
- DePinho, Ronald A
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 1999-05
- Volume
- 97
- Issue
- 4
- Pages
- 527-538
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2027779909
- Cited by
- 979
- References
- 44
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 18 · 2023: 21 · 2022: 15 · 2021: 22 · 2020: 15 · 2019: 26 · 2018: 24 · 2017: 23 · 2016: 32 · 2015: 34 · 2014: 23 · 2013: 40 · 2012: 51
- FWCI
- 36.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01hd028317-05, 5r01hd034880-04, 5k08ar002104-04)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (K08AR02104-01)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD34880, R01 HD28317)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- p53, telomere dysfunction, telomere shortening, telomerase deficiency, telomere crisis, carcinogenesis, genomic instability, tumor suppression, apoptosis, growth arrest, telomere length
- MeSH terms
- Animals, Male, Mice, Inbred C57BL, Neoplasms, Phenotype, Spermatozoa, Testis, Tumor Suppressor Protein p53, Telomere, Apoptosis, Telomerase, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
